Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort

Introduction: Approximately 2% of lung adenocarcinomas have BRAF (v-Raf murine sarcoma viral oncogene homolog B) mutations, including V600E and other types. Vemurafenib, dabrafenib, and sorafenib as BRAF inhibitors are currently tested in clinical trials, but access for patients is limited. The aim of this study was to document the clinical course of patients treated outside of clinical trials. Methods: We conducted a retrospective multicenter cohort study in Europe of patients with advanced BRAF-mutant lung cancer treated with known BRAF inhibitors. Data were anonymized and centrally assessed for age, gender, smoking, histology, stage, local molecular diagnostic results, systemic therapies, and survival. Best response was assessed locally by RECIST1.1. Results: We documented 35 patients treated in 17 centers with vemurafenib, dabrafenib, or sorafenib. Median age was 63 years (range 42–85); gender was balanced; 14 (40%) were never smokers; all (100%) had adenocarcinoma; 29 (83%) had V600E; 6 (17%) had other mutations; one of them had a concomitant KRAS mutation. Thirty (86%) patients had chemotherapy in the first line. Overall survival with first-line therapy was 25.3 months for V600E and 11.8 months for non-V600E. Thirty-one patients received one BRAF inhibitor, and four received a second inhibitor. Overall response rate with BRAF therapy was 53%, and disease control rate was 85%. Median progression-free survival with BRAF therapy was 5.0 months, and overall survival was 10.8 months. Conclusions: These results confirm the activity of targeted therapy in patients with BRAF-mutant lung adenocarcinoma. Further trials are warranted to study combination therapies and drug resistance mechanisms.

[1]  Qing Huang,et al.  BRAF Mutations in Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis , 2014, PloS one.

[2]  Steven P. Angus,et al.  Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF–MEK–ERK Pathway in Cancer , 2014, Clinical Cancer Research.

[3]  M. Brown,et al.  Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial , 2012, The Lancet.

[4]  S. Peters,et al.  Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. , 2013, Lung cancer.

[5]  C. Gridelli,et al.  Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Y. Huang,et al.  Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  M. Socinski,et al.  Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC , 2014, Expert opinion on pharmacotherapy.

[8]  Antonio Marchetti,et al.  Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Peters,et al.  Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[11]  Jeanne Shen,et al.  Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.

[12]  M. Ladanyi,et al.  Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Ascierto,et al.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.

[14]  C. Rudin,et al.  Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  P. Ashton-Prolla,et al.  494PGENOMIC ALTERATIONS IN PATIENTS SHOWING MULTIPLE PRIMARY TUMORS AND FAMILY HISTORY OF CANCER. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  M. Joerger,et al.  Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma. , 2015, Lung cancer.

[17]  L. Horn.  Advances in the treatment of non-small cell lung cancer. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[18]  M. Ladanyi,et al.  Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  T. Eberlein,et al.  Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .

[20]  E. Álava,et al.  Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  F Levi,et al.  European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  S. Aebi,et al.  A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  Sourav Bandyopadhyay,et al.  Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer , 2014, Proceedings of the National Academy of Sciences.

[24]  N. Hayward,et al.  Molecular Pathways: Mitogen-Activated Protein Kinase Pathway Mutations and Drug Resistance , 2013, Clinical Cancer Research.

[25]  J. Soria,et al.  Immune checkpoint inhibitors in advanced nonsmall cell lung cancer , 2015, Current opinion in oncology.

[26]  Edward S. Kim,et al.  The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.

[27]  M. Socinski,et al.  LBA38_PRDABRAFENIB IN PATIENTS WITH BRAF V600E-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A MULTICENTER, OPEN-LABEL, PHASE II TRIAL (BRF113928) , 2014 .

[28]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[29]  C. Belani,et al.  Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer , 2015, PloS one.

[30]  M. Ladanyi,et al.  Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium , 2015, Cancer.

[31]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[32]  Olivier Michielin,et al.  Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Ladanyi,et al.  Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches , 2015, Clinical Cancer Research.

[34]  Junfeng Xia,et al.  BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. , 2012, Cancer discovery.

[35]  Frank McCormick,et al.  Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond , 2014, Nature Reviews Cancer.

[36]  A. Yoshizawa,et al.  Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer. , 2011, Anticancer research.

[37]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[38]  Li Ding,et al.  Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers , 2012, Cell.

[39]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[40]  Roman K. Thomas,et al.  Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  T. Kohno,et al.  Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  J. Mosser,et al.  Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts). , 2013 .

[43]  J. O’Shaughnessy,et al.  BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. , 2014, Lung cancer.

[44]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[45]  K. Huebner,et al.  B-raf and a B-raf pseudogene are located on 7q in man. , 1992, Oncogene.

[46]  J. Blay,et al.  VE-BASKET, a first-in-kind, phase II, histology-independent "basket" study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m). , 2014 .